open access

Vol 65, No 9 (2007)
Other
Published online: 2007-10-03
Submitted: 2012-12-28
Get Citation

Original article
Cardiac troponin I in patients with chronic kidney disease treated conservatively or undergoing long-term haemodialys

Mariusz Flisiński, Paweł Stróżecki, Anna Stefańska, Grażyna Zarzycka-Lindner, Andrzej Brymora, Jacek Manitius
Kardiol Pol 2007;65(9):1068-1075.

open access

Vol 65, No 9 (2007)
Other
Published online: 2007-10-03
Submitted: 2012-12-28

Abstract

Background: Cardiac troponin I (cTnI) has been shown to be a specific marker of myocardial damage in the general population. In patients suffering from chronic kidney disease (CKD) cTnI may be increased in serum without other signs of acute myocardial damage confusing the diagnosis.
Aim: To compare cTnI concentration in CKD patients, treated conservatively or with haemodialysis, with healthy controls, and to evaluate the cardiovascular risk factor profile in these groups.
Methods: The study population consisted of three groups: group I (n=10, 5 women, 5 men, mean age 32±4 years) – healthy, young volunteers without kidney diseases with creatinine clearance (CrCl) 97.13±23.24 ml/min; group II (n=21, 8 women, 13 men, mean age 51±15 years) – patients with CKD in stages 3-5 with CrCl=34.04±18.34 ml/min; and group III (n=30, 14 women, 16 men, mean age 50±14 years) – patients on long-term haemodialysis. The cTnI level was measured using an AxSYM analyzer (Abbott). In group III blood was taken before the haemodialysis session. The high sensitivity C-reactive protein (hsCRP), haemoglobin, parathyroid hormone (PTH) and phosphorus levels were determined. Blood pressure was also recorded. Echocardiography was performed and left ventriclular mass index (LVMI) was calculated on the basis of the Devereux and Reichek formula.
Results: Compared with controls, the cTnI values were significantly higher in patients from group III and tended to be higher in patients from group II (0.01±0.03 vs. 0.063±0.08 and 0.066±0.162 ng/ml, respectively, p

Abstract

Background: Cardiac troponin I (cTnI) has been shown to be a specific marker of myocardial damage in the general population. In patients suffering from chronic kidney disease (CKD) cTnI may be increased in serum without other signs of acute myocardial damage confusing the diagnosis.
Aim: To compare cTnI concentration in CKD patients, treated conservatively or with haemodialysis, with healthy controls, and to evaluate the cardiovascular risk factor profile in these groups.
Methods: The study population consisted of three groups: group I (n=10, 5 women, 5 men, mean age 32±4 years) – healthy, young volunteers without kidney diseases with creatinine clearance (CrCl) 97.13±23.24 ml/min; group II (n=21, 8 women, 13 men, mean age 51±15 years) – patients with CKD in stages 3-5 with CrCl=34.04±18.34 ml/min; and group III (n=30, 14 women, 16 men, mean age 50±14 years) – patients on long-term haemodialysis. The cTnI level was measured using an AxSYM analyzer (Abbott). In group III blood was taken before the haemodialysis session. The high sensitivity C-reactive protein (hsCRP), haemoglobin, parathyroid hormone (PTH) and phosphorus levels were determined. Blood pressure was also recorded. Echocardiography was performed and left ventriclular mass index (LVMI) was calculated on the basis of the Devereux and Reichek formula.
Results: Compared with controls, the cTnI values were significantly higher in patients from group III and tended to be higher in patients from group II (0.01±0.03 vs. 0.063±0.08 and 0.066±0.162 ng/ml, respectively, p
Get Citation

Keywords

troponin I; chronic kidney disease; haemodialysis; LVMI; hsCRP

About this article
Title

Original article
Cardiac troponin I in patients with chronic kidney disease treated conservatively or undergoing long-term haemodialys

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 65, No 9 (2007)

Pages

1068-1075

Published online

2007-10-03

Bibliographic record

Kardiol Pol 2007;65(9):1068-1075.

Keywords

troponin I
chronic kidney disease
haemodialysis
LVMI
hsCRP

Authors

Mariusz Flisiński
Paweł Stróżecki
Anna Stefańska
Grażyna Zarzycka-Lindner
Andrzej Brymora
Jacek Manitius

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl